CHINA BIOLOGIC PRODS HLDGS I's ticker is CBPO and the CUSIP is G21515104. A total of 88 filers reported holding CHINA BIOLOGIC PRODS HLDGS I in Q3 2020. The put-call ratio across all filers is 0.11 and the average weighting 1.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $1,759,000 | -4.9% | 14,851 | -5.1% | 0.00% | 0.0% |
| Q4 2020 | $1,849,000 | -17.0% | 15,656 | -21.9% | 0.00% | -50.0% |
| Q3 2020 | $2,229,000 | +8.7% | 20,056 | -0.1% | 0.00% | 0.0% |
| Q2 2020 | $2,051,000 | -23.9% | 20,068 | -19.7% | 0.00% | 0.0% |
| Q1 2020 | $2,696,000 | -36.6% | 24,978 | -31.7% | 0.00% | -33.3% |
| Q4 2019 | $4,254,000 | -11.0% | 36,556 | -12.4% | 0.00% | -25.0% |
| Q3 2019 | $4,779,000 | +14.1% | 41,745 | -5.0% | 0.00% | +33.3% |
| Q2 2019 | $4,188,000 | -25.1% | 43,945 | -28.3% | 0.00% | -40.0% |
| Q1 2019 | $5,593,000 | +10.6% | 61,291 | -8.0% | 0.01% | 0.0% |
| Q4 2018 | $5,058,000 | -4.0% | 66,635 | +1.2% | 0.01% | 0.0% |
| Q3 2018 | $5,269,000 | +54.1% | 65,857 | +91.3% | 0.01% | +66.7% |
| Q2 2018 | $3,419,000 | -65.1% | 34,424 | -71.5% | 0.00% | -70.0% |
| Q1 2018 | $9,800,000 | +4.7% | 120,986 | +1.8% | 0.01% | +11.1% |
| Q4 2017 | $9,364,000 | – | 118,884 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kite Lake Capital Management (UK) LLP | 207,382 | $24,135,000 | 76.46% |
| Maso Capital Partners Ltd | 539,597 | $62,798,000 | 20.20% |
| York Capital Management Global Advisors, LLC | 1,102,163 | $128,270,000 | 7.40% |
| HHLR ADVISORS, LTD. | 2,751,200 | $320,185,000 | 3.99% |
| Dalton Investments, Inc. | 15,551 | $1,810,000 | 1.14% |
| Athos Capital Ltd | 8,290 | $965,000 | 0.96% |
| Myriad Asset Management Ltd. | 67,019 | $7,799,000 | 0.94% |
| Temasek Holdings (Private) Ltd | 990,000 | $115,216,000 | 0.75% |
| OXFORD ASSET MANAGEMENT LLP | 211,646 | $24,631,000 | 0.68% |
| AGF Investments America Inc. | 12,230 | $1,423,000 | 0.47% |